吞功能障碍,耐力和消化障碍症状严重程度的比较在早期阿尔茨海默病和年龄相匹配的对照中
Emel Arslan-Sarımehmetoğlu1, Zilan Bazancir-Apaydin2
1Department of Speech and Language Therapy, Faculty of Health Sciences/Ankara Medipol University, Ankara, Turkey.
概括
患有早期阿尔茨海默氏病 (AD) 的人表现出吞功能障碍,与健康对照人相比,10毫升水吞测试的持续时间更长. 这种测试可能表明消化不良,需要在阿尔茨海默病患者早期查.
科学领域:
- 神经学 神经学
- 胃肠病学 胃肠病学
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 吞功能障碍 (吞障碍) 是早期阿尔茨海默病的潜在并发症.
- 在AD患者和健康对照者 (HCs) 中比较吞功能对于了解疾病影响至关重要.
研究的目的:
- 在早期的AD和HC中,比较吞功能障碍,耐力和消化不良症状的严重程度.
- 为了确定与阿德的吞困难相关的因素.
- 评估特定的吞测试在检测AD的吞障碍时的有用性.
主要方法:
- 一项涉及25名阿尔茨海默氏症患者和15名年龄相匹配的HC患者的病例控制研究.
- 吞功能障碍通过10毫升和100毫升的水吞测试来评估.
- 使用重复唾液吞测试 (RSST) 评估吞耐力.
- 用饮食评估工具-10 (EAT-10) 测量过敏症症状的严重程度.
主要成果:
- 与HC相比,患有AD的人的10毫升水吞测试持续时间明显长 (p=0.019).
- 对于EAT-10分数,100毫升水吞测试持续时间或RSST结果,两组之间没有发现显著差异.
- 在AD组中,EAT-10得分与疾病持续时间 (r=0.451,p=0.031) 和零食消费 (r=-0.404,p=0.045) 相相关.
- 100毫升水吞试验的持续时间与AD组的体重指数 (BMI) 相对应 (r=-0.559,p=0.004).
结论:
- 早期阿尔茨海默病的吞困难与疾病持续时间,BMI和零食摄入量有关.
- 10毫升水吞测试可以作为阿兹海默症患者的消化不良的指标.
- 早期食障碍查对阿兹海默症患者至关重要,以预防并发症和指导干预.
相关概念视频
01:26Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
01:30Dementia
173
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
173
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265